MichaelMLedermanMD

Infectious Disease • Cleveland, OH

Professor, Medicine, Case Western Reserve University School of Medicine

Join to view full profile

Dr. Lederman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lederman's full profile

Already have an account?

Office
11100 Euclid Ave
Cleveland, OH 44106
Phone+1 216-844-8500

Fax+1 216-844-5356

Education & Training

Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1977 - 1978
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1975 - 1976
Case Western Reserve University/University Hospitals Cleveland Medical CenterInternship, Internal Medicine, 1974 - 1975
Icahn School of Medicine at Mount SinaiClass of 1974
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Infectious Disease

Certifications & Licensure

OH State Medical License 1980 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)
Completed
Phase 2
A Pilot Study of Allogeneic Lymphocyte Transfer in HIV Infection
Completed
Not Applicable
The Effects of Treatment for Mycobacterium Avium Complex (MAC) on the Cells of HIV-Infected Patients
Completed
Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315
Completed
Phase 2
A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328
Completed
Not Applicable
The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients
Completed
Not Applicable
A Study to Evaluate the Ability of TNFR:Fc to Decrease the Amount of IL-6 (Interleukin-6) and TNF-alpha (Tumor Necrosis Factor) in HIV-Infected Patients
Completed
Not Applicable
Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
Completed
Not Applicable
A Study of HIV-Disease Development in Aging Start of enrollment: 2000 Oct 01
Completed
Phase 2
Increasing HAART-Induced Immune Restoration With Cyclosporine
Completed
Phase 2
Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs Start of enrollment: 2005 Apr 01
Completed
Phase 1
Safety of and Immune Response to a Hepatitis B Virus Vaccine Given With a Booster (CpG7909 ODN) in HIV Infected and HIV Uninfected People Start of enrollment: 2004 Dec 01
Completed
Phase 1, Phase 2
Safety Study of IL-7 in HIV-infected Patients (Inspire) Start of enrollment: 2007 May 01
Completed
Phase 1
Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure Start of enrollment: 2008 Sep 01
Completed
Phase 4
Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients Start of enrollment: 2009 Dec 01
Unknown status
Not Applicable
Study on Interleukin-7 (CYT107) in HIV Patients Start of enrollment: 2010 Jan 01
Terminated
Phase 2
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir Start of enrollment: 2013 Apr 25
Completed
Phase 4
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study) Start of enrollment: 2014 Jan 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

2578 citations
Microbial translocation is a cause of systemic immune activation in chronic HIV infection
Jason M. Brenchley, David Price, Timothy W. Schacker, Tedi E. Asher, Guido Silvestri
Nature Medicine. 2006-11-19
83 citations
CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection.
Christoph Lange, Hernan Valdez, Kathy Medvik, Robert Asaad, Michael M. Lederman
Clinical Immunology. 2002-02-01
14 citations
Statins Blunt HAART-Induced CD4 T-Cell Gains but Have No Long-Term Effect on Virologic Response to HAART.
Benigno Rodriguez, Hernan Valdez, Anne M Mijch, Kerrie Watson, Michael M. Lederman
Journal of the International Association of Physicians in AIDS Care. 2007-06-19

Journal Articles

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Is Predictive of Non-AIDS Events During Antiretroviral Therapy-Mediated Viral Suppression
Michael M Lederman, Jochen Reiser, Clinical Infectious Diseases
Safety and Impact of Low-Dose Methotrexate on Endothelial Function and Inflammation in Individuals with Treated Human Immunodeficiency Virus: AIDS Clinical Trials Grou...
Steven G Deeks, James H Stein, Carl Fichtenbaum, Judith S Currier, Priscilla Y Hsue, Eric S Daar, Ahmed Tawakol, Michael Lederman, Tanvir Bell, Diane Havlir, Clinical Infectious Diseases
Effect of Antiretroviral Therapy on Plasma Concentrations of Chloroquine and Desethyl-Chloroquine
Charles Flexner, Michael M Lederman, Theresa A Shapiro, Clinical Infectious Diseases

Press Mentions

COVID, Quo Vadis? Michael LedermanJune 19th, 2022
Liver Fibrosis Index FIB‐4 Is Associated with Mortality in COVID‐19December 10th, 2020
Dr. Michael Lederman Proposes Mandatory COVID-19 Vaccines & RegistriesJuly 30th, 2020
Join now to see all

Grant Support

Case AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases2007–2012
Defining The Pathogenesis Of Immune Deficiency In Chronic HIV InfectionNational Institute Of Allergy And Infectious Diseases2008–2011
Bystander Activation Drives T Cell Losses In Chronic HIV InfectionNational Institute Of Allergy And Infectious Diseases2008–2011
Administrative CoreNational Institute Of Allergy And Infectious Diseases2008–2011
Developing Rantes Analogues As Topical Strategies To Prevent HIV TransmissionNational Institute Of Allergy And Infectious Diseases2008–2010
Basic And Comparative Studies Of CCR5 Inhibition To Prevent HIV TransmissionNational Institute Of Allergy And Infectious Diseases2008–2010
Administrative CoreNational Institute Of Allergy And Infectious Diseases2008–2010
Core--Clinical CoreNational Institute Of Allergy And Infectious Diseases2004–2008
2007 Case CFAR Annual Spring ConferenceNational Institute Of Allergy And Infectious Diseases2007
Topical Immune Modulatory Strategies To Prevent HIV TransmissionNational Institute Of Allergy And Infectious Diseases2006–2007
Center For AIDS Research(Cfar)National Institute Of Allergy And Infectious Diseases2004–2007
Case CFAR Meeting: HIV PathogenesisNational Institute Of Allergy And Infectious Diseases2006
ACTG 5214 Single Dose IL-7 In HIV-1 Subjects Receiving Antiretroviral TreatmentNational Center For Research Resources2006
Topical Agents To Prevent Mucosal HIV TransmissionNational Institute Of Allergy And Infectious Diseases2002–2006
Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1992–2006
Phase II Study Of Glivic In African Kaposi'S SarcomaNational Institute Of Allergy And Infectious Diseases2005
Conference On HIV PathogenesisNational Institute Of Allergy And Infectious Diseases2005
Antiretroviral Outcomes And Resistance In African WomenNational Institute Of Allergy And Infectious Diseases2005
Immune Mechanisms And HIV Disease PathogenesisNational Institute Of Allergy And Infectious Diseases2004
ACTG A5147s Lopinavir/Ritonavir VS Gw433908 In HIV-1 PTS With Treatment FailureNational Center For Research Resources2004
Center For AIDS Research (CFAR)National Institute Of Allergy And Infectious Diseases1999–2003
Safety &Antiviral Activity Of AMD3100 In HIV-1 InfectionNational Center For Research Resources2000–2002
ACTG 928--Tnf Receptor On IL6, TNF Alpha, &Immune Markers In HIVNational Center For Research Resources2000–2002
ACTG 398--Amprenavir/Abacavir/Efavirenz/Adeforvir Dipivoxil In HIV InfectionNational Center For Research Resources2000–2002
ACTG 384--Protease Inhibitor Or Reverse Transcriptase Inhibitor In HIV InfectionNational Center For Research Resources2000–2002
ACTG 301: Memantine For AIDS Dementia ComplexNational Center For Research Resources1999–2002
ACTG 328--Intermittent Recombinant Human Interleukin-2National Center For Research Resources1998–2002
Core--Clinical ResearchNational Institute Of Allergy And Infectious Diseases1994–2002
Development Of HIV Coreceptor InhibitorsNational Institute Of Allergy And Infectious Diseases1998–2001
Viral Activation Transfusion StudyDivision Of Blood Diseases And Resources1995–2000
Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Outreach AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Neurology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases1996–1999
Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Actg--Safety, Tolerability &Antiviral Activity Of Thalidomide In HIVNational Center For Research Resources1997
AIDS Clinical TrialsNational Institute Of Allergy And Infectious Diseases1994–1995
Adult AIDS Clinical ResearchNational Institute Of Allergy And Infectious Diseases1992–1995
Procysteine TM To Placebo In HIV Infected PTS Taking Antiretroviral NucleosideNational Center For Research Resources1994
Oral RO 24-7429 (Tat Antagonist) In Patients With HIV InfectionNational Center For Research Resources1994
Pharmacokinetics Of Oral Procysteine Effects On GlutathioneNational Center For Research Resources1993
Oral RO 24-7429 (Tat Antagonist) In Patients With HIV InfectionNational Center For Research Resources1993
IV Procysteine In Patients Infected With Hiv--Effects On Levels Of GlutathioneNational Center For Research Resources1993
Rifampin, Ciproflaxacin, Clofazimine, Ethambutol, &Amikacin In HIV+ IndividualsNational Center For Research Resources1992–1993
Procysteine In Patients Infected With Hiv--Effects On Levels Of GlutathioneNational Center For Research Resources1992–1993
Establishment Of An AIDS Clinical Studies GroupNational Institute Of Allergy And Infectious Diseases1987–1991
Clinical Trials Study GroupNational Institute Of Allergy And Infectious Diseases1987–1991
Establishment Of AIDS Clinical Studies GroupNational Institute Of Allergy And Infectious Diseases1990
Zidovudine For Asymptomatic HIV Infected IndividualsNational Center For Research Resources1990
Trial Of A Single Dosing Schedule Of Zidovudine In Early AIDS Related ComplexNational Center For Research Resources1990
Niaid Treatment Regimens For Pneumocystis Carinii In AIDSNational Center For Research Resources1990
AIDS Study--Fluconazole &Amphotericine-B For Cryptococcal MeningitisNational Center For Research Resources1990
ACTG Study In Aids--2'3'Dideoxyinosine &Azt For Aids/Arc Patients On AZT TherapyNational Center For Research Resources1990
Mechanisms Of Cell Loss In HIV InfectionsNational Institute Of Allergy And Infectious Diseases1987–1989